Glaxosmithkline Pharmaceuticals Ltd vs Unjha Formulations Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2120 as of 12 Jun 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 37.3 on March 2026 . This represents a CAGR of -9.55% over 6 yearsThe P/E Ratio of Unjha Formulations Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 38682 crore on March 2026 . This represents a CAGR of 7.98% over 6 yearsThe Market Cap of Unjha Formulations Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Unjha Formulations Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Unjha Formulations Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Unjha Formulations Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 95.44 % on March 2026 . This represents a CAGR of -6.42% over 6 yearsThe Dividend Payout of Unjha Formulations Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' in 1987 and was again changed to 'GlaxoSmithKline Pharmaceuticals Limited' dated October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is the Indian subsidiary of GSK plc, a UK-based, science-led global healthcare organisation focused on uniting science, technology and talent to get ahead of disease.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Unjha Formulations Ltd

Unjha Formulations Limited was established in June, 1987 as a Partnership firm for manufacturing pharmaceutical formulations in the Mehsana district of Gujarat.
The Company is a pioneer in Isabgol (Psyllium) Formulation.
The Company is in service to Isabgol (Psyllium) Ayurvedic formulation profession. The company manufactures pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles, etc.
It is one of the largest manufacturers of isabgul products in India.
The company's products are classified under two divisions -- human consumption and veterinary products. Its parent company M/S Urvesh Ltd. is 100% EOU is engaged in exporting of Isabol Husk & Isabgol Powder.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Unjha Formulations Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Unjha Formulations Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 35,925 Cr while Market cap of Unjha Formulations Ltd is 8 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Unjha Formulations Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Unjha Formulations Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Unjha Formulations Ltd?

As of June 15, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2120.7. On the other hand, Unjha Formulations Ltd stock price is INR ₹19.7.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Unjha Formulations Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Unjha Formulations Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.